Fierce Pharma: After price cuts, Eli Lilly inks in $13.5M settlement in long-running insulin lawsuit


The lawsuit was filed against insulin makers Sanofi, Novo Nordisk and Lilly in 2017 for purposefully raising the price of their insulin. As part of the $13.5M settlement, Lilly has agreed to cap its out-of-pocket insulin prices at $35 for the next four years. Sanofi and Novo Nordisk have also agreed to cap their insulin costs, but have yet to reach a settlement in the lawsuit.

Click here to read the whole article by Kevin Dunleavy for Fierce Pharma.

Comments are closed.

Skip to toolbar